Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening

British Journal of Cancer

Volumn 78, Issue 12, 1998, Pages 1586-1593

  Boven, E ^a,c   Pinedo, H M ^a   Van Hattum, A H ^a   Scheffer, P G ^a   Peters, W H M ^b   Erkelens, C A M ^a   Schluper H M M ^a   Kuiper, C M ^a   Van Ark Otte, J ^a   Giaccone, G ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti cancer agents; Glutathione; Glutathione dependent enzymes; MDR1; Soft tissue sarcoma xenografts; Topoisomerase II

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; VINCRISTINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVITY; FEMALE; HISTIOCYTOMA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEIOMYOSARCOMA; LIPOSARCOMA; MOUSE; NEUROFIBROSARCOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SARCOMA; SOFT TISSUE SARCOMA; TUMOR GROWTH; XENOGRAFT;

EID: 7744247582     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.727     Document Type: Article

References (40)

1. Black SM and Wolf CR (1991) The role of glutathione-dependent enzymes in drug resistance. Pharm Ther 5: 139-154
2. Boven E (1991a) Characterization and monitoring. In The Nude Mouse in Oncology Research. Boven E and Winograd B (eds), pp. 89-101. CRC Press: Boca Raton, FL
3. Boven E (1991b) Analogs of conventional agents. In The Nude Mouse in Oncology Research. Boven E and Winograd B (eds), pp. 185-198. CRC Press: Boca Raton, FL
4. Boven E, Calame JJ, Molthoff CFM and Pinedo HM (1989) Characterization and chemotherapy of human soft tissue sarcoma lines grown in nude mice. Strahlenther Onkol 165: 538-539
5. Boven E, Schlüper HMM, Erkelens CAM and Pinedo HM (1990) Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. Eur J Cancer Clin Oncol 26: 983-986
6. Boven E, Winograd B, Fodstad Ø, Lobbezoo MW and Pinedo HM (1988) Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol 24: 527-573
7. Boven E, Winograd B, Berger DP, Dumont P, Braakhuis BJM, Fodstad Ø, Langdon S and Fiebig HH (1992) Phase II preclinical drug screening in human tumor xenografts - a first European multicenter collaborative study. Cancer Res 52: 5940-5947
8. Bramwell VHC, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verweij J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R and Van Oosterom A (1987) Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23: 311-321
9. Broxterman HJ, Feller N, Kuiper CM, Boven E, Versantvoort CHM, Teerlink T and Pinedo HM (1995) Correlation between functional and molecular analysis of MDRI P-glycoprotein in human solid-tumor xenografts. Int J Cancer 61: 880-886
10. Budach W, Budach V, Stuschke M, Schmander B, Reipke P and Scheulen ME (1994) Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts. Br J Cancer 70: 29-34
11. Carlberg I and Mannervik B (1985) Glutathione reductase. Methods Enzymol 113: 484-490
12. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
13. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant GE, Wilson GM and Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910
14. Demetri GD and Elias AD (1995) Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Hematol Oncol Clin North Am 9: 765-785
15. Dirix LY and Van Oosterom A (1989) The role of ifosfamide in the treatment of sarcomas. Semin Oncol 16(suppl. 3): 39-45
16. Feit C, Bartal AH, Fass B, Bushkin Y, Cordon Cardo C and Hirshaut Y (1994) Monoclonal antibodies to human sarcoma and connective tissue differentiation antigens. Cancer Res 44: 5752-5756
17. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW and Hickson ID (1991) Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592-6595
18. Giaccone G, Gazdar AF, Beck H, Zunino F and Capranico G (1992) Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666-1674
19. Habig WH, Pabst MJ and Jakoby WB (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249: 7130-7139
20. Hayes JD and Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprevention and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600
21. Hida T, Ariyoshi Y, Kuwabara M, Sugiura T, Takahashi T, Takahashi T, Hosoda K, Niitsu Y and Ueda R (1993) Glutathione S-transferase π levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn J Clin Oncol 23: 14-19
22. Jansen WJM, Pinedo HM, Kuiper CM, Lincke C, Bamberger U, Heckel A and Boven E (1994) Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole. Ann Oncol 5: 733-739
23. Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T and Saijo N (1992) Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84: 113-118
24. Klumper E, Giaccone G, Pieters R, Broekema G, Van Ark-Otte J, Van Wering ER, Kaspers GJL and Veerman AJP (1995) Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia. Leukemia 9: 1653-1660
25. Langdon SP, Hendriks HR, Braakhuis BJM, Pratesi G, Berger DP, Fodstad O, Fiebig HH and Boven E (1994) Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol 5: 415-422
26. Lawrence RA and Burk RF (1976) Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 71: 952-958
27. Moltholf CFM, Calame JJ, Pinedo HM and Boven E (1991) Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer 47: 72-79
28. Neuschwander-Tetri BA and Roll FJ (1989) Glutathione measurement by high-performance liquid chromatography separation and fluorometric detection of the glutathione-orthophtalaldehyde adduct. Anal Biochem 179: 236-241
29. Nitiss JL and Beck WT (1996) Antitopoisomerase drug action and resistance. Eur J Cancer 32A: 958-966
30. Peters WHM, Boon CEW, Roelofs HMJ, Wobbes T, Nagengast FM and Kremers PG (1992) Expression of drug metabolizing enzymes and p-glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology 103: 448-455
31. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Bucsa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, Van Glabbeke M and Van Oosterom A (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-1545
32. Sharma R, Singhal SS, Srivastava SK, Bajpai KK, Frenkel EP and Awasthi S (1993) Glutathione and glutathione linked enzymes in human small cell lung cancer cell lines. Cancer Lett 75: 111-119
33. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH and Wrigley PFM (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333-1340
34. Slovak ML, Pelkey HJ, Cole SPC, Deeley RG, Greenberger L, De Vries EGE, Broxterman HJ, Scheffer GL and Scheper RJ (1995) The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55: 4214-4219
35. Stein U, Shoemaker RH and Schlag PM (1996) MDRI gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 32A: 86-92
36. Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320
37. WHO (1979) Handbook for Reporting Results of Cancer Treatment. Publication No. 48. World Health Organization: Geneva
38. Winograd B, Boven E, Lobbezoo MW and Pinedo HM (1987) Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development. In Vivo 1: 1-14
39. Yang JC, Rosenberg SA, Glatstein EJ and Antman KH (1993) Sarcomas of soft tissues. In Cancer, Principles and Practice of Oncology. DeVita VT, Hellman S and Rosenberg SA (eds), pp. 1436-1488. JB Lippincott Company: Philadelphia, PA
40. Yellin SA, Davidson BJ, Pinto JT, Sacks PG, Qiao C and Schantz SP (1994) Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines. Cancer Lett 85: 223-232